Rafferty Asset Management, LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$5,719,847
-16.7%
807,888
-17.1%
0.03%
-12.8%
Q2 2023$6,863,740
+0.3%
974,963
+18.8%
0.04%
-15.2%
Q1 2023$6,843,145
-22.4%
820,521
+6.8%
0.05%
-37.8%
Q4 2022$8,817,478
+35.8%
768,073
+49.1%
0.07%
+7.2%
Q3 2022$6,492,000
+58.4%
515,228
+33.0%
0.07%
+81.6%
Q2 2022$4,098,000
-24.0%
387,327
+16.8%
0.04%
+18.8%
Q1 2022$5,394,000
-14.0%
331,713
-26.7%
0.03%
-3.0%
Q4 2021$6,269,000
+112.8%
452,637
+120.8%
0.03%
+65.0%
Q3 2021$2,946,000
+19.4%
204,998
+31.3%
0.02%
+25.0%
Q2 2021$2,468,000
-7.9%
156,107
-40.8%
0.02%
-11.1%
Q1 2021$2,681,000
+220.3%
263,584
+134.6%
0.02%
+125.0%
Q4 2020$837,000
-53.7%
112,351
-78.7%
0.01%
-63.6%
Q3 2020$1,808,000
+70.4%
526,302
+136.4%
0.02%
+46.7%
Q2 2020$1,061,000
+3020.6%
222,617
+1194.3%
0.02%
+1400.0%
Q1 2020$34,000
-93.3%
17,200
-88.2%
0.00%
-87.5%
Q4 2019$504,000
-35.1%
146,084
-46.2%
0.01%
-33.3%
Q3 2019$777,000
-46.1%
271,376
-28.7%
0.01%
-52.0%
Q2 2019$1,442,000
+68.7%
380,494
+262.2%
0.02%
+78.6%
Q1 2019$855,000105,0400.01%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q1 2021
NameSharesValueWeighting ↓
DG Capital Management, LLC 1,186,726$4,076,0002.45%
Sarissa Capital Management LP 4,861,000$16,697,0001.97%
Ghost Tree Capital, LLC 1,950,000$6,698,0001.94%
ORACLE INVESTMENT MANAGEMENT INC 2,525,857$8,676,0001.14%
Eversept Partners, LP 1,143,211$3,926,9300.87%
DAFNA Capital Management LLC 749,051$2,573,0000.84%
KNOTT DAVID M 397,361$1,365,0000.80%
Parkman Healthcare Partners LLC 800,740$2,751,0000.73%
ACUTA CAPITAL PARTNERS, LLC 660,000$2,267,0000.62%
Formidable Asset Management, LLC 578,200$1,949,0000.57%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders